Completion of dosing for 5,041 subjects in the Phase 2b NAVIGATE clinical trial, indicating significant progress in the development of CD388 for influenza prevention. Publication of preclinical data ...
Additional clinical-stage programs, including a Phase 2/3 trial in advanced melanoma, underscore momentum across the company’s oncology pipeline Eikon Therapeutics, Inc., a late-stage clinical ...
Celcuity (CELC) recently released positive results from its phase 3 VIKTORIA-1 trial, which used its drug gedatolisib in combination with other therapies to treat patients with PIK3CA wildtype ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback